AbbVie Inc. said another phase 3 clinical trial of risankizumab in plaque psoriasis patients met its main goal.
Results from the IMMhance study showed that after 16 weeks of treatment, patients in the risankizumab arm experienced an improvement in their condition when compared to placebo.
Furthermore, in the risankizumab arm, 87% of the patients maintained improvement in disease until the end of one year. In the group that switched to placebo, 61% of the patients maintained improvements.
Top-line results announced in October showed that after 16 weeks of treatment, the drug was better at treating moderate to severe chronic plaque psoriasis when compared to ustekinumab, adalimumab or placebo.
AbbVie is developing risankizumab in collaboration with Boehringer Ingelheim GmbH.
The drug is also being evaluated in Crohn's disease, ulcerative colitis and psoriatic arthritis.